Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer.

ABSTRACT:

Introduction

Delays from primary surgery to chemotherapy are associated with worse survival in ovarian cancer, however the impact of delays from neoadjuvant chemotherapy to interval debulking surgery is unknown. We sought to evaluate the association of delays from neoadjuvant chemotherapy to interval debulking with survival.

Methods

Patients with a diagnosis of stage III/IV ovarian cancer receiving neoadjuvant chemotherapy from July 2015 to December 2017 were included in our analysis. Delays from neoadjuvant chemotherapy to interval debulking were defined as time from last preoperative carboplatin to interval debulking >6 weeks. Fisher's exact/Wilcoxon rank sum tests were used to compare clinical characteristics. The Kaplan-Meier method, log-rank test, and multivariate Cox P

SUBMITTER: Liu YL 

PROVIDER: S-EPMC9049059 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature